Search research articles
Contact Us
Filters
Showing results (141-150 of 157) with videos related to
Page
of 16
Sort By:
Molecular Cancer Research : MCR
|
March 13, 2020
Destruction of a Microtubule-Bound MYC Reservoir during Mitosis Contributes to Vincristine's Anticancer Activity
Sabrina Becker, Christina Kiecke, Eva Schäfer, et al.
Cell Reports
|
October 12, 2022
PARP-inhibition reprograms macrophages toward an anti-tumor phenotype
Lin Wang, Dan Wang, Olmo Sonzogni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
U A Matulonis, G M Wulf, W T Barry, et al.
Research Square
|
January 30, 2023
Reciprocal inhibition of PIN1 and APC/C<sub>CDH1</sub> controls timely G1/S transition and creates therapeutic vulnerability
Shizhong Ke, Fabin Dang, Lin Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2016
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
Joyce F Liu, Sangeetha Palakurthi, Qing Zeng, et al.
Cell
|
October 15, 2013
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells
William J Israelsen, Talya L Dayton, Shawn M Davidson, et al.
Cell
|
August 13, 2021
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
Kazuhiro Koikawa, Shin Kibe, Futoshi Suizu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2020
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M Tung, Mark E Robson, Steffen Ventz, et al.
Nature Communications
|
April 15, 2024
Reciprocal antagonism of PIN1-APC/C<sup>CDH1</sup> governs mitotic protein stability and cell cycle entry
Shizhong Ke, Fabin Dang, Lin Wang, et al.
Breast Cancer Research : BCR
|
July 7, 2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Yan Xing, Nancy U Lin, Matthew A Maurer, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 157) with videos related to
Sort By:
Page
of 16
Molecular Cancer Research : MCR
|
March 13, 2020
Destruction of a Microtubule-Bound MYC Reservoir during Mitosis Contributes to Vincristine's Anticancer Activity
Sabrina Becker, Christina Kiecke, Eva Schäfer, et al.
Cell Reports
|
October 12, 2022
PARP-inhibition reprograms macrophages toward an anti-tumor phenotype
Lin Wang, Dan Wang, Olmo Sonzogni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
U A Matulonis, G M Wulf, W T Barry, et al.
Research Square
|
January 30, 2023
Reciprocal inhibition of PIN1 and APC/C<sub>CDH1</sub> controls timely G1/S transition and creates therapeutic vulnerability
Shizhong Ke, Fabin Dang, Lin Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2016
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
Joyce F Liu, Sangeetha Palakurthi, Qing Zeng, et al.
Cell
|
October 15, 2013
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells
William J Israelsen, Talya L Dayton, Shawn M Davidson, et al.
Cell
|
August 13, 2021
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
Kazuhiro Koikawa, Shin Kibe, Futoshi Suizu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2020
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M Tung, Mark E Robson, Steffen Ventz, et al.
Nature Communications
|
April 15, 2024
Reciprocal antagonism of PIN1-APC/C<sup>CDH1</sup> governs mitotic protein stability and cell cycle entry
Shizhong Ke, Fabin Dang, Lin Wang, et al.
Breast Cancer Research : BCR
|
July 7, 2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Yan Xing, Nancy U Lin, Matthew A Maurer, et al.
Page
of 16